Solasta Bio develops peptide-based, nature-inspired bioinsecticides designed to selectively target insect pests while protecting beneficial pollinators such as bees. Its technology platform can be mobilized for any pest across crop and non-crop applications, including stored grain. The company’s agents demonstrated efficacy on par with or better than commercial standards across more than 20 field trials in Europe, the UK and the US during the 2023 trials season. Co-founded by CEO Shireen Davies and CSO Prof. Julian Dow, Solasta is based in Glasgow, Scotland. The company recently closed a $14M Series A, bringing total capital raised to $19M, and intends to use the funds to accelerate development of its peptide-based bioinsecticides. Forbion’s involvement will also add a board seat as part of the round. SOLASTA Bio develops next‑generation green insecticides based on nature‑inspired peptides that target pests selectively. The company's core products are sustainable peptide insect control solutions intended to replace or augment conventional chemical insecticides. SOLASTA was announced as the winner of the Radicle Natural Plant Protection (NPP) Challenge by UPL, which the company says will help accelerate its solutions toward the global market. As part of the prize, SOLASTA will gain industry support and access to UPL Corp and Radicle Growth's networks and expertise to help commercial development. The company was selected from a pool of 237 start‑up applicants, highlighting external validation of its technology. No revenue, user, or founding‑year metrics were disclosed in the announcement. Solasta Bio has developed a technology platform for creating neuropeptide-based insect control products that are nature-inspired rather than selected from a synthetic chemistry library. Its products target insect pests while preserving beneficial pollinators such as bees, and the platform can be mobilised for any pest of interest. The company plans to use the funds to scale up UK and US operations, expand its technical and commercial teams (creating 25 jobs), accelerate development of its technology platform and target new markets. Solasta is led by CEO Shireen Davies, PhD, with CSO Professor Julian Dow and former BASF executive Dr Paul Bernasconi among the team; other executives include Chair Dr Rob Wylie, CFO David Armour and CCO Dr Daphne Preuss. The company currently employs a team of 25 R&D, commercial staff and consultants. The fundraising round brings the company's total funding to £5.5M. Solasta Bio develops biopesticides using a technology platform that creates neuropeptide-based insect control products inspired by nature rather than synthetic-chemistry libraries. Its products are designed to target insect pests while preserving beneficial pollinators such as bees. The company was established in May 2020 following four years of research funded by UKRI BBSRC and the EC, with commercialisation support from Scottish Enterprise’s High Growth Spinout Programme. Management includes co-founders Professor Shireen Davies (CEO), Professor Julian Dow (CSO), Paul Bernasconi (CTO) and Professor Robert Liskamp, supported by a Glasgow-based R&D team. Financially, Solasta secured £1.3m in seed funding and had earlier pre-seed backing from UKI2S and Scottish Enterprise. The company plans to move trials out of the laboratory into real-world settings and aims to bring its first biopesticides to market in 2027, roughly half the development time of traditional synthetic products.

Total raised

$22M

Funding rounds

4

Latest round

Series A

Latest activity

Sep 2024